Genetic Variant Protects Against Kidney Disease by Regulating Zinc Levels

Kidney disease affects over 850 million people globally and represents the third fastest-growing cause of mortality, yet therapeutic options remain severely limited. This groundbreaking study identifies a novel genetic pathway that could revolutionize kidney disease treatment.

Researchers analyzed UK Biobank data covering twelve different kidney diseases and discovered that only one genetic variant—rs13107325 in the SLC39A8 gene—was associated with all conditions studied. This variant causes an amino acid change (A391T) in the ZIP8 protein, which normally transports zinc and manganese into cells.

Using genetically engineered mice carrying this variant, scientists found remarkable protection against both acute kidney injury (from ischemia-reperfusion) and chronic kidney disease (from ureteral obstruction). The protective mechanism involves reduced zinc accumulation in kidney tubular cells, which activates the zinc-AKT-FOXO1-G6PC cellular pathway that prevents kidney damage.

Most significantly, the researchers demonstrated that zinc chelation therapy using EDTA could replicate these protective effects in normal mice, offering immediate therapeutic potential. This treatment significantly prevented and ameliorated both acute and chronic kidney disease in experimental models.

The findings establish renal zinc homeostasis as a critical therapeutic target, with implications for treating diverse kidney pathologies through a unified mechanism. This represents a paradigm shift from treating individual kidney diseases to targeting the underlying zinc dysregulation that contributes to multiple forms of kidney damage.